Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.69 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | CDK7 | P50613 | 12/20 | 0.69 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | JAK1 | P23458 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 2/20 | 0.54 |
| ▸ | PLK4 | O00444 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PAK4 | O96013 | 1/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | PRKCG | P05129 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627833 | 0.89 | FGFR1 (0.81) | FGFR1FGFR3FGFR2CDK7PIM1 | |
| SCHEMBL18812677 | 0.86 | CDK7 (0.63) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL761113 | 0.85 | JAK2 (0.62) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL31040239 | 0.84 | FGFR1 (0.65) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL627899 | 0.84 | FGFR1 (0.65) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL2482107 | 0.82 | FLT3 (0.59) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL2480608 | 0.82 | FLT3 (0.59) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL14404446 | 0.82 | CDK7 (0.58) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL16934639 | 0.81 | CDK7 (0.57) | FGFR1FGFR3FGFR2CDK7JAK2 | |
| SCHEMBL4008807 | 0.81 | CDK2 (0.70) | FGFR1FGFR3FGFR2CDK7JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1820503-B1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA SRL (IT) | 2012-02-22 | — | — | EP | disclosed |
| EP-1432416-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2011-01-19 | — | — | EP | disclosed |
| US-7511136-B2 | Aminoindazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2009-03-31 | — | — | US | disclosed |
| EP-1820503-A2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | Pfizer Italia S.r.l. (IT) | 2007-08-22 | — | — | EP | disclosed |
| CN-1556702-A | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | — | 2004-12-22 | — | — | CN | disclosed |
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2004-12-16 | — | — | US | disclosed |
| EP-1432416-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003028720-A1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254177-A1 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K15, MAP3K3, MAP3K5 | FGFR1 3752/4885FGFR3 3612/4885FGFR2 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.